Accelerating Brain Tumor Research and Care

Summary#

The BRAIN Act aims to speed up research and improve care for people with brain tumors. It expands National Institutes of Health (NIH) efforts, increases public awareness of clinical trials and biomarker testing, and supports better long‑term care for survivors. The broad goal is to develop new treatments, help patients access trials, and improve quality of life.

Key changes:

• Requires NIH‑funded brain tumor biospecimen collections (such as tumor tissue and spinal fluid) to be reported to a public, searchable website so researchers can find them. NIH may withhold funding for repeated or serious violations.
• Authorizes $50 million per year (FY2026–FY2030) for the Glioblastoma Therapeutics Network to move therapies from early studies into first‑in‑human trials.
• Authorizes $10 million per year (FY2026–FY2030) for multi‑institution “team science” awards to advance brain tumor cellular immunotherapies, including CAR‑T, for adults and children.
• Directs a national public awareness campaign on cancer clinical trials and biomarker testing, with targeted outreach to high‑risk, rural, and other communities, plus grants to test outreach strategies.
• Funds NIH pilot programs to develop and study models of lifelong monitoring and care for brain tumor survivors, including care coordination and mental health supports.
• Requires FDA to issue guidance within one year to reduce unnecessary exclusion of brain tumor and rare cancer patients from clinical trials for other diseases.

What it means for you#

• Patients and families

  • You may see more information and outreach on how cancer clinical trials work, how to enroll, and how to access biomarker testing.
  • Over time, you could see more early‑phase trials for glioblastoma and for cellular immunotherapies (including CAR‑T) at major centers.
  • New pilot programs may improve post‑treatment care plans, care coordination between specialists and primary care, and access to psychosocial support.
  • FDA guidance could make it easier for some brain tumor patients to join trials that previously excluded them.
  • These changes focus on research and care models. They do not create new treatment approvals or insurance coverage by themselves.

• Health care providers (physicians, nurses, cancer centers, children’s hospitals, community facilities)

  • You may receive new materials and participate in outreach efforts on trials and biomarker testing.
  • Eligible institutions can apply for NIH funding for survivorship care pilots and for team‑based immunotherapy research.
  • You may be asked to adopt or test new care coordination and survivorship tools, including secure electronic sharing of treatment summaries and follow‑up plans.

• Researchers, biobanks, and NIH‑funded institutions

  • If you hold NIH‑funded brain tumor biospecimens, you must report collection details to NIH (existing collections within 180 days; new collections within 60 days). Noncompliance can lead to funding being withheld for repeated or serious violations.
  • New funding opportunities will support glioblastoma therapy development and multi‑site cellular immunotherapy trials.

• Rural and underserved communities

  • The awareness campaign must include culturally and linguistically competent messages and target rural and other priority communities.

• General public

  • The bill mainly affects research, clinical trials, and specialized care. Day‑to‑day impact for most people is indirect.

Expenses#

Estimated public cost: The bill authorizes up to about $335 million over FY2026–FY2030 if fully funded by future appropriations.

• Glioblastoma Therapeutics Network: $50 million per year for FY2026–FY2030 (total $250 million).
• Brain tumor cellular immunotherapy team science awards (including CAR‑T): $10 million per year for FY2026–FY2030 (total $50 million).
• National awareness campaign and demonstration projects on trials and biomarker testing: $10 million total for FY2026–FY2030.
• Survivorship care pilot programs: $5 million per year for FY2026–FY2030 (total $25 million).
• Creating/maintaining the biospecimen website(s) and issuing FDA guidance may add administrative costs. No publicly available information.
• Reporting requirements may create compliance costs for institutions that hold NIH‑funded biospecimens. No publicly available information.

Proponents' View#

• The bill appears intended to address long‑standing poor survival rates and the small number of approved brain tumor treatments by investing in targeted research areas (glioblastoma and cellular immunotherapy).
• Publicly listing NIH‑funded biospecimen collections could make it easier for researchers to find needed samples, reduce duplication, and speed studies.
• A national campaign on clinical trials and biomarker testing could help more patients understand options, talk with their doctors, and join appropriate trials.
• Survivorship pilots may develop practical models to improve follow‑up care, care coordination, mental health supports, and quality of life.
• FDA guidance to reduce trial exclusions could broaden access to promising treatments for brain tumor and rare cancer patients.
• Targeted outreach to high‑risk, rural, and diverse communities could help address gaps in awareness and participation.

Opponents' View#

• One concern is added administrative burden: NIH‑funded labs and biobanks must report biospecimen collections on tight timelines, with the risk of funding being withheld for repeated or serious noncompliance.
• The bill does not detail exactly what data must be reported beyond aligning with an existing NIH locator; this may create uncertainty until NIH sets requirements.
• Authorized funding requires future congressional appropriations; if not fully funded, programs may be limited in scope or delayed.
• FDA guidance is advisory; it may not, by itself, change trial eligibility rules or sponsor practices.
• The bill promotes biomarker testing and trial awareness but does not create insurance coverage or payment mandates, so access may still vary by plan and location.
• The $10 million total for national awareness and outreach over five years may be modest for a nationwide effort.